<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="kwz110TB1" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <p>Summary of 5 Dengue Serosurveys in Singapore, 2004–2017</p>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col align="left" span="1"/>
   <col align="center" span="1"/>
   <col align="char" char="–" span="1"/>
   <col align="char" char="." span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
  </colgroup>
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Survey</th>
    <th rowspan="1" colspan="1">Agency or Institution</th>
    <th rowspan="1" colspan="1">Age Range, years</th>
    <th rowspan="1" colspan="1">Sample Size (
     <italic>n</italic>)
    </th>
    <th rowspan="1" colspan="1">Survey Period</th>
    <th rowspan="1" colspan="1">ELISA Test
     <sup>a</sup>
    </th>
    <th rowspan="1" colspan="1">Source (First Author, Year (Reference No.))</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">National Health Survey
     <sup>b</sup>
    </td>
    <td rowspan="1" colspan="1">MOH</td>
    <td rowspan="1" colspan="1">18–74</td>
    <td rowspan="1" colspan="1">4,152</td>
    <td rowspan="1" colspan="1">September–December 2004</td>
    <td rowspan="1" colspan="1">Panbio Dengue IgG Indirect ELISA
     <sup>c</sup>
    </td>
    <td rowspan="1" colspan="1">Yew, 2009 (
     <xref rid="kwz110C24" ref-type="bibr">24</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">National Paediatric Seroprevalence Survey
     <sup>b</sup>
    </td>
    <td rowspan="1" colspan="1">MOH</td>
    <td rowspan="1" colspan="1">2–15</td>
    <td rowspan="1" colspan="1">984</td>
    <td rowspan="1" colspan="1">August 2008–July 2010</td>
    <td rowspan="1" colspan="1">EUROIMMUN Anti-Dengue Virus ELISA (IgG)
     <sup>d</sup>
    </td>
    <td rowspan="1" colspan="1">Ang, 2015 (
     <xref rid="kwz110C25" ref-type="bibr">25</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">2009 seroprevalence survey
     <sup>b</sup>
    </td>
    <td rowspan="1" colspan="1">NEA/EHI</td>
    <td rowspan="1" colspan="1">16–60</td>
    <td rowspan="1" colspan="1">3,627</td>
    <td rowspan="1" colspan="1">December 2009–February 2010</td>
    <td rowspan="1" colspan="1">Panbio Dengue IgG Indirect ELISA</td>
    <td rowspan="1" colspan="1">Low, 2015 (
     <xref rid="kwz110C21" ref-type="bibr">21</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">2013 seroprevalence survey</td>
    <td rowspan="1" colspan="1">NEA/EHI</td>
    <td rowspan="1" colspan="1">16–71</td>
    <td rowspan="1" colspan="1">3,813</td>
    <td rowspan="1" colspan="1">December 2013–February 2014</td>
    <td rowspan="1" colspan="1">Panbio Dengue IgG Indirect ELISA</td>
    <td rowspan="1" colspan="1">Present study</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">2017 seroprevalence survey</td>
    <td rowspan="1" colspan="1">NEA/EHI</td>
    <td rowspan="1" colspan="1">16–74</td>
    <td rowspan="1" colspan="1">4,002</td>
    <td rowspan="1" colspan="1">June–August 2017</td>
    <td rowspan="1" colspan="1">Panbio Dengue IgG Indirect ELISA</td>
    <td rowspan="1" colspan="1">Present study</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="kwz110tfn1">
   <p>Abbreviations: EHI, Environmental Health Institute; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; MOH, Ministry of Health; NEA, National Environment Agency.</p>
  </fn>
  <fn id="kwz110tfn2">
   <p>
    <sup>a</sup> The sensitivity (Panbio: 97.9%; EUROIMMUN: 100%) and specificity (Panbio: 100%; EUROIMMUN: 100%) of the Panbio and EUROIMMUN assays (as provided in the product inserts) were similar. Both assays were tested in a serum sample panel of patients with suspected dengue virus infection (n = 87), and the qualitative results of the two ELISAs were 99% in agreement (EUROIMMUN Anti-Dengue Virus ELISA (IgG) product information). This shows that the data from these studies may be used collectively for analysis. The total number of samples analyzed in these 5 studies was 16,578.
   </p>
  </fn>
  <fn id="kwz110tfn3">
   <p>
    <sup>b</sup> A brief description of prior studies can be found in 
    <xref ref-type="supplementary-material" rid="sup1">Web Appendix 1</xref>.
   </p>
  </fn>
  <fn id="kwz110tfn4">
   <p>
    <sup>c</sup> Alere Inc., Waltham, Massachusetts.
   </p>
  </fn>
  <fn id="kwz110tfn5">
   <p>
    <sup>d</sup> EUROIMMUN AG, Lübeck, Germany.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
